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Abstract
Background: Metabolic syndrome (MetS) is associated with an increased risk of the development of
atherosclerotic cardiovascular disease (CVD). Interleukin-18 (IL-18), which is a pleiotropic proinflammatory cytokine
with important regulatory functions in the innate immune response system, plays a crucial role in vascular
pathologies. IL-18 is also a predictor of cardiovascular death in patients with CVD and is involved in atherosclerotic
plaque destabilization.
Results: In order to determine if circulating levels of IL-18 can serve as a specific biomarker for distinguishing MetS
patients from pre-MetS subjects, we studied 78 patients with visceral fat deposition and 14 age-matched control
subjects. Increased levels of IL-18 were observed more frequently in patients with MetS than in pre-MetS subjects
and were positively associated with waist circumference. Serum levels of IL-18 were significantly reduced by a
change in weight caused by lifestyle modifications. There was a significant interaction between waist
circumference and serum IL-18 concentration. Weight loss of at least 5% of the body weight caused by lifestyle
modification decreased IL-18 circulating levels relative to the reduction in waist circumference and blood pressure,
suggesting that this degree of weight loss benefits the cardiovascular system.
Conclusion: IL-18 may be a useful biomarker of the clinical manifestations of MetS and for the management of
the risk factors of CVD.
Background
Obesity and the related metabolic syndrome (MetS) are
major public health problems [1] that are associated with
an increased risk of the development of atherosclerotic
cardiovascular disease (CVD). The mechanism of which
may be mediated, at least in part, by increased secretion of
proinflammatory cytokines by the adipose tissue [2]. MetS
consists of atherogenic dyslipidemia (elevated triglycerides
and low high-density lipoproteins [HDLs]), elevated blood
pressure and glucose levels, and abdominal obesity with
prothrombotic and proinflammatory states [1]. MetS is
associated with a 5-fold higher risk of the development
of type 2 diabetes and a 2.6- to 3-fold higher risk of
the development of CVD [3,4]. The pathophysiology
underlying MetS is not well defined, and several investiga-
tors have sought to identify a single factor that could
explain all of the components of the syndrome. In addition
to insulin resistance and/or hyperinsulinemia, investigators
have found several biomarkers that are associated with
MetS, including leptin [3], catecholamines [5], brain
natriuretic peptide (BNP) [6], oxidized low-density lipo-
protein (LDL) cholesterol [7], uric acid [8], C-reactive pro-
tein (CRP) [3], plasminogen activator inhibitor-1 [3],
aldosterone [3], cystatin C [9], and carboxy-terminal
prevasopressin (copeptin) [10]. This wide variety of bio-
markers highlights the diverse pathophysiological pertur-
bations that occur in MetS [10].
Interleukin-18 (IL-18), which is a pleiotropic proin-
flammatory cytokine with important regulatory functions
in the innate immune response system, plays a crucial
role in vascular pathologies. IL-18 is also known as a pre-
dictor of cardiovascular death in CVD patients and is
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A growing body of evidence suggests that IL-18 levels
may be closely related to MetS and its consequences
[11-13]. Increasing levels of circulating IL-18 have been
reported to be closely associated with the components of
MetS and to predict type 2 diabetes, cardiovascular
events, and mortality [14,15]. IL-18 is secreted constitu-
tively in many different cell types in the adipose tissue,
including macrophages, vascular endothelial cells, vascu-
lar smooth muscle cells, and adipocytes [16,17]. On the
other hand, aerobic exercise has been reported to reduce
levels of CRP and IL-18 in subjects with type 2 diabetes
[18,19].
We hypothesized that circulating levels of IL-18 may
enhance atherosclerosis-prone conditions in patients
with MetS. In order to examine this hypothesis, we stu-
died the circulating levels of IL-18 in MetS patients and
in subjects with pre-MetS conditions. Furthermore, the
circulating levels of IL-18 were examined in MetS
patients before and after lifestyle modifications that
resulted in weight loss.
Results and Discussion
Results
Circulating IL-18 levels as a specific biomarker to
distinguish MetS patients from subjects with pre-MetS
conditions
In order to determine whether the circulating levels of
IL-18 could be a specific biomarker to distinguish MetS
patients from subjects with pre-MetS conditions, we stu-
died 42 patients with MetS or pre-MetS and 14 control
subjects (average body mass index [BMI], 23.3). There
were 28 patients diagnosed as having MetS (BMI, 30.9),
and the remaining 14 patients were designated as pre-
MetS (BMI, 29.6), which was defined as the subjects
having only 1 component of the MetS criteria proposed
by the Japanese Society of Internal Medicine. The base-
line characteristics of the subjects are shown in Tables 1
and 2. Patients with MetS had a higher BMI and waist
circumference.
As shown in Table 2, fasting plasma glucose levels,
plasma insulin levels, a homeostasis model assessment
(HOMA-IR), and triglyceride levels increased in both
MetS and pre-MetS subjects. Among them, only plasma
insulin levels were significantly higher in patients with
MetS compared to those who were pre-MetS. These
data suggest that more severe hyperinsulinemia may
exist in MetS patients compared to subjects with pre-
MetS conditions.
Increased levels of glycated hemoglobin (HbA1c), CRP,
and IL-18 were observed in MetS patients (Table 3).
Decreased serum adiponectin levels were observed in
patients with both MetS and pre-MetS compared with
those in control subjects (Figure 1a). There was no differ-
ence in adiponectin levels between MetS and pre-MetS
patients (Table 3). Increased levels of CRP and IL-18
likely reflect a low-grade systemic inflammation and the
development of atherosclerosis.
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observed more frequently in patients with MetS than in
those who were pre-MetS (P < 0.01), and these levels
were positively associated with fasting insulinemia (P <
0.05). Interestingly, serum levels of IL-18 were slightly,
but significantly, correlated with the waist circumference in
patients with MetS and pre-MetS conditions (Figure 1c).
These data suggest that IL-18 may reflect visceral fat
deposition and insulin resistance. In conclusion, IL-18
may be a useful biomarker of the clinical manifestations
of MetS and for the management of the risk factors of
CVD.
Circulating IL-18 as a useful biomarker for lifestyle
modification
We hypothesized that body weight loss from lifestyle
modification would improve systemic inflammation in
patients with MetS. Serum IL-18 levels were measured
in 57 patients with MetS (average BMI, 32.0) before and
after they lost at least 5% of their initial weight by life-
style modification. As shown in Table 4, subjects in the
study were typically abdominally obese patients, 74% of
the subjects were diagnosed with hypertension, and 61%
had diabetes mellitus (DM) and/or impaired fasting glu-
cose (IFG). There was a significant interaction between
serum CRP levels and IL-18 levels in patients with MetS
(P < 0.01).
Among all of the subjects undergoing lifestyle modifi-
cations, 89% achieved significant reductions in weight,
Table 1 Characteristics of the study participants
Characteristics MetS
(n = 28)
Pre-MetS
(n = 14)
Control
(n = 14)
Age (year) 54.8 ± 12.9 58.9 ± 13.0 56.4 ± 10.1
Sex, female (%) 9 (32.1%) 6 (42.9%) 8 (57.1%)
BMI (kg/m
2) 30.9 ± 7.7* 27.6 ± 3.2 23.3 ± 2.9
Waist circumference (cm) 102.7 ± 13.2*
# 95.0 ± 7.5* 78.7 ± 7.2
Data are means ± SD. *P < 0.01 for MetS (or pre-MetS) vs. Control.
#P < 0.01
for MetS vs. pre-MetS. BMI, body mass index; MetS, metabolic syndrome.
Table 2 Components of the metabolic syndrome
Components MetS Pre-MetS Control
Plasma glucose (mg/dL) 136 ± 50* 110 ± 12 99 ± 7
Plasma insulin (IU/mL) 8.7 ± 5.6*
# 6.3 ± 2.7 5.2 ± 1.5
HOMA-IR 2.0 ± 1.1* 1.7 ± 0.7* 1.3 ± 0.4
HDL cholesterol (mg/dL) 48 ± 12* 59 ± 16* 71 ± 16
Triglyceride (mg/dL) 187 ± 25* 160 ± 24* 69 ± 21
Hypertension, n (%) 21 (75.0%)* 5 (35.7%)
# 3 (21.4%)
Data are means ± SD. *P < 0.01 for MetS (or pre-MetS) vs. Control.
#P < 0.05
for MetS vs. pre-MetS. HOMA-IR, homeostatis model assessment; HDL, high
density lipoprotein; MetS, metabolic syndrome.
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after the lifestyle modification was maintained for an
average of 22.6 (5.6) weeks. As shown in Table 5, 22-23
weeks of lifestyle modification could significantly reduce
obese conditions, including body weight and waist cir-
cumference. Systolic blood pressure was also markedly
reduced in these subjects (P < 0.01).
Serum levels of IL-18 were significantly reduced with
weight loss (P < 0.01), and the levels significantly corre-
lated with the change in weight (P = 0.046). Lifestyle
modification-induced weight loss of 5% body weight sig-
nificantly improved the levels of circulating biomarkers
that are related to metabolic and vascular inflammation
(Table 6). Most importantly, 5% body weight loss
reduced serum levels of IL-18 and synergistically
increased serum adiponectin levels in these obese
patients (Figure 2).
The reduction in IL-18 concentration correlated with
increases in adiponectin (P =0 . 0 1 5 ) .A5 %w e i g h tl o s s
Table 3 Interleukin-18 and related biomarkers
MetS Pre-MetS Control
HbA1c (%) 6.3 ± 1.3* 5.4 ± 0.4 5.0 ± 0.3
CRP (μg/dL) 365 ± 272* 114 ± 98 82 ± 55
adiponectin (μg/mL) 5.0 ± 0.7* 5.5 ± 0.8* 6.3 ± 0.9
IL-18 (pg/mL) 301 ± 220*
# 121 ± 31 112 ± 29
Data are means ± SD. *P < 0.05 for MetS (or pre-MetS) vs. Control.
#P < 0.01
for MetS vs. pre-MetS. HbA1c, haemoglobinA1c; CRP, C-reactive protein; IL-18,
interleukin-18; MetS, metabolic syndrome.
Figure 1 Circulating Interleukin-18 (IL-18) as a biomarker in the adipocytokine family. (a) Serum levels of adiponectin. *P < 0.05 for MetS
(or pre-MetS) vs. Control. (b) Circulating levels of IL-18. *P < 0.01 for MetS (or pre-MetS) vs. Control.
#P < 0.01 for MetS vs. pre-MetS. (c) Serum
levels of IL-18 and waist circumference. Correlations: P < 0.01.
Table 4 Baseline characteristics of the study participants
for lifestyle modification
Characteristics Values (range)
Age (year) 55.4 ± 13.2 28-76
Sex, female (%) 27 (54.0%)
Body mass index (kg/m
2) 31.9 ± 6.2 24-61
Body weight (kg) 84.5 ± 18.6 54.5-138
Waist circumference (cm) 104.5 ± 12.0 85.5-144
Systolic blood pressure (mmHg) 138.7 ± 17.7
Diastolic blood pressure (mmHg) 78.3 ± 11.8
Triglyceride (mg/dL) 189.5 ± 121.3
HDL-cholesterol (mg/dL) 50.1 ± 11.5
Plasma glucose (mg/dL) 123.4 ± 37.0
Hypertension (%) 74
High triglyceride (%) 49
Low HDL-cholesterol (%) 11
DM/IFG (%) 61
Values are means ± SD or presence of comorbidities (%). HDL, high-density
lipoprotein; DM, diabetes mellitus; IFG, impaired fasting glucose.
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levels of IL-18 in relation to the reduction in waist
circumference, serum CRP levels, and blood pressure,
suggesting that this degree of weight loss resulted in
cardiovascular benefits.
Discussion
To the best of our knowledge, this is the first study
showing that circulating IL-18 levels can be a useful bio-
marker for distinguishing patients with MetS from sub-
jects with pre-MetS conditions. Furthermore, a 5%
weight loss from lifestyle modification decreased circu-
lating IL-18 levels, a prognostic biomarker for coronary
artery disease, in patients with MetS.
IL-18 and vascular inflammation
In the last decade, accumulating evidence has suggested
the importance of a low but chronic inflammatory state
in obesity and in MetS. Recent research has revealed a
role of adipose tissue beyond energy storage that
involves the harboring of inflammatory cells that are
believed to sustain inflammation and impair adipocyte
function [20,21]. IL-18 was originally found as an inter-
feron-gamma (IFN-g)-inducing factor (IGIF) [22] and
belongs to the IL-1 family of cytokines [23]. The expres-
sion of IL-18 has been reported to be higher in athero-
sclerotic plaques than in normal control arteries. In
addition, IL-18 was found to localize mainly in plaque
macrophages and express strongly in unstable plaques
[24]. These data suggested that IL-18 plays a major role
in atherosclerotic plaque destabilization, which leads to
acute ischemic syndromes. In an atherosclerotic animal
model, murine IL-18 binding protein (the endogenous
inhibitor of IL-18) prevents fatty streak development in
the thoracic aorta of apoE knockout mice and slows the
progression of advanced atherosclerotic plaques in the
aortic sinus [25]. Moreover, IL-18 has been recently
shown to contribute to cardiac dysfunction following
ischemic reperfusion in vitro [26]. These findings, taken
together, identify the inhibition of IL-18 signaling as an
important therapeutic target for preventing atherosclero-
tic plaque development and for inhibiting plaque com-
plications [25].
IL-18 and metabolic syndrome
IL-18 concentrations are increased in patients with type
2 diabetes, obesity, and polycystic ovary syndrome
[27-29]. In addition, circulating IL-18 has been reported
to be closely associated with MetS and its components
[30]. Paradoxically, IL-18-deficient mice had markedly
increased body weight compared with wild type litter-
mates at 3 months of age, and these mice exhibited
obesity, insulin resistance, hyperglycemia, lipid abnorm-
alities, and atherosclerosis. The weight gain was asso-
ciated with significantly increased body fat; food intake;
and glucose, insulin, glucagon, cholesterol, and leptin
levels. A histological analysis of various organs of the
mutant mice showed only an increased size of the pan-
creatic islets. Leptin administration or the intracerebral,
but not intravenous, administration of recombinant IL-
18 reduced food intake. Intraperitoneal administration
of recombinant IL-18 restored insulin sensitivity and
corrected the hyperglycemia through the activation of
signal activation of transcription 3 (STAT3) phosphory-
lation in IL-18 double-knockout mice. These data sug-
gest that IL-18 has an important role in the homeostasis
of energy intake and insulin sensitivity.
In the present study, circulating levels of IL-18 were
significantly reduced after lifestyle modification, which
resulted in a synergistic reduction in serum CRP levels,
Table 6 Changes in circulating interleukin-18 and related
biomarkers by lifestyle modification
before after P values
Triglyceride (mg/dL) 190 ± 121 139 ± 67 0.049
HDL-cholesterol (mg/dL) 50 ± 12 56 ± 11 < 0.001
Glucose (mg/dL) 123 ± 37 105 ± 19 0.041
Adiponectin (μg/mL) 5.4 ± 1.5 6.5 ± 2.1 0.034
IL-18 (pg/mL) 158 ± 97 119 ± 75 0.021
CRP (μg/dL) 311 ± 315 204 ± 219 0.012
Data are means ± SD. HDL, high density lipoprotein; IL-18, interleukin-18; CRP,
C-reactive protein.
Figure 2 Circulating levels of interleukin-18 (IL-18) and
adiponectin in patients with metabolic syndrome before and
after lifestyle modification.* P < 0.05 for baseline vs. after lifestyle
modification in patients with metabolic syndrome.
Table 5 Lifestyle modification-induced changes in
anthropometric variables
Characteristics Values (range)
Δ Body mass index (kg/m
2) 1.6 ± 1.1
# (0.4-5.0)
Δ Body weight (kg) 5.4 ± 4.4
# (2.8-33.0)
Δ Waist circumference (cm) 9.6 ± 5.5* (1.5-24.5)
Δ Systolic blood pressure (mmHg) 15.3 ± 17.5*
Δ Diastolic blood pressure (mmHg) 12.1 ± 19.1
#
Values are means ± SD (range).*P < 0.01 and
#P < 0.05 for baseline vs. after
lifestyle modification in patients with metabolic syndrome.
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with MetS. On the other hand, obese patients with type
2 diabetes have been reported to produce significantly
less IFN-g in the peripheral blood mononuclear cells in
response to IL-18 stimulation compared to lean con-
trols, which was most likely due to the reduced expres-
sion of the IL-18 receptor b chain [31]. This has led to
a new concept of IL-18 resistance, which is similar to
insulin resistance, in MetS patients. This new concept of
IL-18 resistance may shed further light upon the
mechanisms involved in the IL-18-related effect on sys-
temic metabolic disorder. At this point, IL-18-mimetic
agents or interventions, including lifestyle modifications,
may be novel therapeutic strategies for patients with not
only pre-MetS conditions but also MetS and athero-
sclerosis-prone conditions.
IL-18 gene polymorphisms have been shown to be
associated with increased levels of circulating IL-18 [32]
and one such polymorphism was associated with
impaired insulin sensitivity and an increased risk of hav-
ing MetS [33,34]. These findings suggest that IL-18 may
be involved in the pathogenesis of MetS [11]. Therefore,
genetic variations of IL-18 influence circulating levels of
IL-18 and the clinical outcome in patients with coronary
artery disease.
IL-18 as a predictive biomarker for cardiovascular events
In previous studies in patients with documented coron-
ary artery disease, serum IL-18 levels were elevated in
patients with acute coronary syndrome [35] and were a
strong independent predictor of cardiovascular death
[14,36]. In a previous cohort study, circulating IL-18
was the only independent predictor of cardiovascular
mortality in a subgroup with MetS [37]. Moreover, cir-
culating IL-18 levels were a strong and independent pre-
dictor of cardiovascular events in elderly men with MetS
[38]. Increased levels of IL-18 were associated with the
presence of subclinical atherosclerosis, which was evalu-
ated by an examination of the intima media thickness of
the carotid artery [39], and by measurement of arterial
stiffness, which was determined on the basis of brachial
pulse wave propagation [40], after adjustment for tradi-
tional risk factors. However, others have reported that
circulating IL-18 levels were associated with carotid
media thickness in univariate analyses, but not after
adjustment for traditional risk factors [13,41] or in mul-
tiple analyses [42].
IL-18 as a therapeutic biomarker to enhance coronary risk
factor management in MetS patients
A growing body of evidence supports an important role
of IL-18 in the pathogenesis of MetS and atherosclerosis.
In this study, a 5% weight loss from lifestyle modification
decreased circulating levels of IL-18 and CRP. According
to the results of previous clinical studies, weight loss
mediated by calorie-restricted diet interventions [43],
Mediterranean-like diets, and omega-3 fatty acid supple-
mentation [44], or combined interventions with diet and
exercise [45,46], were reported to decrease IL-18 levels
[40]. Aerobic exercise has been reported to reduce circu-
lating levels of IL-18 in patients with type 2 diabetes
[18,19] and IL-18 expression in adipose tissue in obese
subjects [47].
Study limitations
A limitation of the current study is that the study cohort
was small. Since the circulating levels of IL-18 corre-
lated well with the waist circumference in patients with
MetS and subjects with pre-MetS conditions, it is rea-
sonable to speculate that there may have also been a dif-
ference detected between the MetS and pre-MetS
groups, if the group sizes were bigger. However, the
group sizes for the examination of the effects of lifestyle
modification were adequate to reveal significant differ-
ences in the changes in the circulating levels of IL-18
and other inflammatory biomarkers.
Conclusions
In summary, higher circulating levels of IL-18 were
associated with increased MetS scores and systemic
inflammation, which was independent of the presence of
diabetes or dyslipidemia. Circulating IL-18 may be a
novel biomarker for high-risk patients with MetS, and
further studies are warranted in order to assess its utility
as a predictor of the presence of MetS and atherogenic
conditions. These findings suggest that IL-18 dysfunc-
tion or resistance is a novel pathophysiological mechan-
ism underlying insulin resistance and MetS. Moreover, a
5% weight loss from lifestyle modification decreased the
circulating levels of IL-18 relative to the reduction in
waist circumference, vascular inflammation, and blood
pressure, suggesting that this degree of circulating
IL-18-guided weight management may be effective for
cardiovascular benefits and the prevention of cardiovas-
cular events.
Materials and methods
Subjects
The study included 78 Japanese outpatients with
abdominal obesity (waist circumference, >85 cm for
men and >90 cm for women) who consulted for medical
care in the Metabolic Syndrome Clinic, Department of
Cardioangiology, Kitasato University Hospital. All sub-
jects provided informed consent before participating in
this study, and anonymity was maintained by tracing the
patients through their clinical history number.
The project was approved by the Scientific and Ethical
Committee of the Kitasato University School of Medi-
cine, Japan. BMI was calculated as weight divided by
height squared. Systolic and diastolic blood pressures
Yamaoka-Tojo et al. Nutrition & Metabolism 2011, 8:3
http://www.nutritionandmetabolism.com/content/8/1/3
Page 5 of 8were measured after a rest of at least 15 min with a
sphygmomanometer while subjects were in a sitting
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insulin resistance, was calculated as fasting plasma insu-
lin (μU/mL) × glucose (mg/dL)/405 [48]. All subjects
were free from chronic inflammation, immune disease,
acute coronary syndrome, renal and/or liver dysfunction,
malignancy, or immune diseases.
Definitions of MetS and pre-MetS
Metabolic scores were calculated using MetS compo-
nents according to the MetS criteria proposed by the
Japanese Society of Internal Medicine [49]. The score
consisted of 4 independent components, including
abdominal obesity, which was defined as a waist circum-
ference of ≥85 cm in men or ≥90 cm in women; high
triglyceride and/or low HDL-cholesterol levels; hyperten-
sion; and elevated fasting glucose levels. The diagnosis of
hypertension was made on the basis of blood pressure
levels measured at the study visit (≥130/85 mmHg) or a
prior diagnosis of hypertension and current treatment
with antihypertensive medications. DM and/or IFG was
considered present if the subject had a history of diabetes
or had a fasting glucose level of 110 mg/dL or greater.
Participants who had low metabolic scores (1 or 2) were
designated as the pre-MetS subjects, whereas the patients
who had high metabolic scores (3 or 4) were defined as
MetS subjects. There were 64 patients diagnosed as hav-
ing MetS and the remaining 14 patients were designated
as pre-MetS, which was defined as having only 1 compo-
nent of the MetS criteria.
Serum Sample Collection
After an overnight fast, blood serum samples were col-
lected by venipuncture from 78 patients with abdominal
obesity and from 14 healthy donors. The age range of
the healthy donors matched that of the patients. For the
IL-18 biomarker study examining the differences in
IL-18 levels between MetS patients and subjects with
pre-MetS conditions, 36 patients out of the 64 patients
with MetS were excluded because they were taking
metabolic-mimetic agents (statins, anti-diabetic drugs,
and/or colestimide).
Measurement of Clinical Biomarkers
Biochemical markers such as triglycerides, LDL choles-
terol, HDL cholesterol, insulin, plasma glucose, HbA1c,
uric acid, gamma-glutamyl transpeptidase (g-GTP), CRP,
and BNP were measured.
Lifestyle Modification
In order to examine the effects of lifestyle modification
in the IL-18 biomarker study, 64 patients with MetS
were recruited to lose weight in order to improve their
cardiovascular risk factors. We studied 57 patients with
MetS (average BMI, 31.9) who successfully lost at least
5% of their initial weight through lifestyle modification.
All subjects were instructed to maintain a standard mild
energy-restricted diet and to engage in walking for at
least 30 min a day, 5 days a week. Serum IL-18 and adi-
ponectin levels were measured in these subjects before
and after lifestyle modification, which was maintained
for 8-34 weeks.
Measurement of Adipocytokines
Circulating levels of human IL-18 and adiponectin were
determined by an enzyme-l i n k e di m m u n o s o r b e n ta s s a y
(ELISA) using the human IL-18 ELISA Kit (MBL, Co.,
Ltd., Nagoya, Japan) and the CircuLex™ human adipo-
nectin ELISA Kit (CycLex Co., Ltd., Nagano, Japan),
respectively. Samples were processed according to the
manufacturer’s instructions [35,50].
Statistical Analysis
Continuous data are summarized as either mean (SD) or
median and quartiles, and categorical data are expressed
a sp e r c e n t a g e s .T h ed a t aw e r ec o m p a r e db ya nu n p a i r e d
t-test or Mann-Whitney U-tests, where appropriate. Dif-
ferences in the proportions of variables were determined
by a chi-squared analysis. In order to evaluate the relation-
ship between IL-18 and selected variables, we calculated
Spearman correlation coefficients between the circulating
levels of fasting IL-18 and the following variables: (1) con-
ventional risk factors for CVD (i.e., LDL cholesterol, HDL
cholesterol, triglycerides, HbA1c, the presence of hyper-
tension, and current smoking status), and history of cor-
onary artery disease; (2) measures of adiposity and insulin
resistance (i.e., BMI, waist circumference, fasting blood
glucose levels, insulin levels, and HOMA-IR); and (3) meta-
bolic risk scores (i.e., abdominal obesity, hypertension,
high triglycerides and/or low HDL cholesterol, and glucose
intolerance or diabetes) and MetS-related co-morbid
conditions (i.e., hyper-uric acidemia, fatty liver disease,
chronic kidney disease, and sleep apnea syndrome).
In order to evaluate the association of IL-18 with
MetS, we constructed multivariable logistic regression
models in order to assess whether the circulating IL-18
levels were independently associated with MetS. We cal-
culated the odds ratio for the presence of MetS in each
IL-18 level quartile, and the participants with IL-18
levels in the lowest IL-18 quartile were considered as
the reference group. Adjustments were performed for
age and sex and for age, sex, and b-blocker use. Two-
sided P-values of < 0.05 were considered significant.
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